TW201008594A - Stable pharmaceutical formulations - Google Patents

Stable pharmaceutical formulations Download PDF

Info

Publication number
TW201008594A
TW201008594A TW098115697A TW98115697A TW201008594A TW 201008594 A TW201008594 A TW 201008594A TW 098115697 A TW098115697 A TW 098115697A TW 98115697 A TW98115697 A TW 98115697A TW 201008594 A TW201008594 A TW 201008594A
Authority
TW
Taiwan
Prior art keywords
solution
agent
pharmaceutical
additive
aqueous
Prior art date
Application number
TW098115697A
Other languages
English (en)
Chinese (zh)
Inventor
James E Kipp
Joseph C T Wong
Lakshmy Nair
Reagan Miller
Barrett E Rabinow
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of TW201008594A publication Critical patent/TW201008594A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW098115697A 2008-05-15 2009-05-12 Stable pharmaceutical formulations TW201008594A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5330108P 2008-05-15 2008-05-15

Publications (1)

Publication Number Publication Date
TW201008594A true TW201008594A (en) 2010-03-01

Family

ID=40941781

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098115697A TW201008594A (en) 2008-05-15 2009-05-12 Stable pharmaceutical formulations

Country Status (8)

Country Link
US (2) US8183233B2 (cg-RX-API-DMAC7.html)
EP (1) EP2288338A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520889A (cg-RX-API-DMAC7.html)
CN (1) CN102026621A (cg-RX-API-DMAC7.html)
CA (1) CA2722602A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010012451A (cg-RX-API-DMAC7.html)
TW (1) TW201008594A (cg-RX-API-DMAC7.html)
WO (1) WO2009140162A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CA2695697A1 (en) 2007-08-07 2009-02-12 Advanced Technologies And Regenerative Medicine, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
BRPI0911048A2 (pt) 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
CN102614491B (zh) * 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
AU2012327237A1 (en) * 2011-12-02 2013-06-20 University Health Network Compositions of tigecycline and uses thereof
HRP20161703T1 (hr) 2012-11-20 2017-03-10 Fresenius Kabi Usa, Llc Formulacije kaspofungin acetata
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
WO2015105720A1 (en) * 2014-01-07 2015-07-16 Hospira Inc. Stabilised carbapenem compositions
US20170190742A1 (en) * 2014-05-29 2017-07-06 Shanghai Techwell Biopharmaceutical Co., Ltd. Composition of cyclic peptide compound, preparation method for same, and uses thereof
KR101587420B1 (ko) * 2014-08-20 2016-01-22 주식회사 대웅제약 에르타페넴-함유 동결건조제제의 제조방법
PL3058958T3 (pl) * 2015-02-23 2019-02-28 Selectchemie Ag Kompozycja anidulafunginy
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
WO2018112330A1 (en) 2016-12-16 2018-06-21 Baxter International Inc. Micafungin compositions
US11968975B2 (en) * 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens
WO2023205165A1 (en) * 2022-04-22 2023-10-26 Brii Biosciences Offshore Limited A polymyxin composition and methods for producing the same
CN117088974B (zh) * 2023-08-14 2024-02-13 武汉健昊生物科技有限公司 一种抗体保存液

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2908614A (en) * 1954-08-10 1959-10-13 Glaxo Lab Ltd Use of dextran in freeze-drying process
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
ES2097120T3 (es) 1989-07-24 1997-04-01 Bayer Ag Estabilizacion de proteinas altamente purificadas.
JPH051075A (ja) * 1991-06-25 1993-01-08 Lederle Japan Ltd カルバペネム化合物を安定に含有する水溶液
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JPH0769887A (ja) * 1993-07-09 1995-03-14 Takeda Chem Ind Ltd ペネム化合物含有固形組成物、その製造法および剤
JPH0920688A (ja) * 1995-07-01 1997-01-21 Hideyo Yamaguchi 抗菌用剤
SE9803517D0 (sv) * 1998-10-15 1998-10-15 Astra Ab Pharmaceutical preparation
HK1040062A1 (zh) 1999-03-03 2002-05-24 Eli Lilly And Company 含有成胶束表面活性剂的棘白菌素药物配方
US7094601B2 (en) * 2000-05-16 2006-08-22 The General Hospital Corporation Microinjection of cryoprotectants for preservation of cells
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20030138403A1 (en) * 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JPWO2006078066A1 (ja) * 2005-01-21 2008-06-19 大日本住友製薬株式会社 経気道呼吸器感染症治療剤
WO2007133711A2 (en) 2006-05-12 2007-11-22 Adventrx Pharmaceuticals, Inc. Pharmaceutical compositions for vein irritating drugs
WO2007142212A1 (ja) * 2006-06-08 2007-12-13 Dainippon Sumitomo Pharma Co., Ltd. 製剤組成物
KR20090045262A (ko) * 2006-08-29 2009-05-07 다이이찌 산쿄 가부시키가이샤 1-메틸카르바페넴 화합물의 동결 건조 제제
BRPI0720125A2 (pt) 2006-12-06 2014-01-28 Wyeth Corp Método para armazenar uma formulação líquida; método para a preparação de uma formulação líquida; composição; e método para inibir a agregação induzida por manitol de uma proteína em uma formulação líquida.
CA2675602A1 (en) 2007-02-16 2008-08-21 Wyeth Protein formulations containing sorbitol

Also Published As

Publication number Publication date
EP2288338A1 (en) 2011-03-02
US20120207762A1 (en) 2012-08-16
US20090286764A1 (en) 2009-11-19
CA2722602A1 (en) 2009-11-19
WO2009140162A1 (en) 2009-11-19
MX2010012451A (es) 2010-12-07
JP2011520889A (ja) 2011-07-21
US8183233B2 (en) 2012-05-22
CN102026621A (zh) 2011-04-20

Similar Documents

Publication Publication Date Title
TW201008594A (en) Stable pharmaceutical formulations
JP2002502810A5 (cg-RX-API-DMAC7.html)
JP2002502810A (ja) エポシロン組成物
CN102712677A (zh) 脂肽组合物和相关方法
US12220441B2 (en) Formulations of vancomycin
CN103118663A (zh) 卡泊芬净组合物
CN101500571A (zh) 稳定的冻干制剂
KR101753949B1 (ko) 가용화제로서의 산을 포함하는 아가트로반 제제
CN117858696A (zh) 一种能皮下给药的抗生素药物组合物
EP3554474B1 (en) Micafungin compositions
JP2011137048A (ja) 新たな用途の薬学的調製物およびその調製物を製造するためのプロセス
US20240293396A1 (en) Ready-to-administer hydromorphone formulations
US20110224175A1 (en) Formulations of canfosfamide and their preparation
HK1156861A (en) Stable pharmaceutical formulations
JP7423028B2 (ja) ボルテゾミブを含有する凍結乾燥医薬組成物
WO2023214433A1 (en) Stable parenteral compositions of parecoxib